Dyax Corp. Appoints Ron Cohen, M.D. and Paolo Pucci to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for
unmet medical needs, announced today the appointment of Ron Cohen, M.D.
and Paolo Pucci to its Board of Directors. In addition to their
appointment as Directors, Dr. Cohen will serve on the Compensation
Committee of the Board, and Mr. Pucci will serve on the Audit Committee.
"Ron and Paolo are each highly regarded innovators and leaders in the
biotechnology industry whose insights will add great value to the Board
of Directors," said Henry E. Blair, Chairman of Dyax's Board of
Directors. "We welcome them to Dyax and look forward to their
contributions as the Company continues to grow each of its three core
franchises, including KALBITOR® (ecallantide), the Licensing and Funded
Research Program and the internal pipeline."
Ron Cohen, M.D.
Dr. Ron Cohen is the Founder, President and Chief Executive Officer of
Acorda Therapeutics, a biotechnology company developing therapies for
multiple sclerosis, spinal cord injury and related nervous system
disorders. Previously, he was a principal and officer at the startup
Advanced Tissue Sciences, Inc. Dr. Cohen is Chairman of the Emerging
Company Section of the Biotechnology Industry Organization (BIO) and a
member of the Executive Committee of the Board of BIO. He previously
served as Director and Chairman of the New York Biotechnology
Association. He also serves as a member of the Columbia-Presbyterian
Health Sciences Advisory Council. Dr. Cohen received his B.A. with
honors in Psychology from Princeton University and his M.D. from the
Columbia College of Physicians & Surgeons. He completed his residency in
Internal Medicine at the University of Virginia Medical Center and is
Board Certified in Internal Medicine.
Paolo Pucci is Chief Executive Officer and member of the Board of
Directors of ArQule Inc., a clinical-stage biotechnology company that is
researching and developing innovative cancer therapeutics targeting
critical biological processes implicated in a wide range of cancers.
Prior to ArQule, Mr. Pucci was at Bayer AG, where he held sequential
responsibilities as Country Head Bayer Italy Pharmaceuticals, President
& SVP Bayer Pharmaceuticals North America - Global Specialty
Pharmaceuticals, and member of the Bayer Pharmaceuticals Executive
Committee, concluding his tenure as president in charge of the
Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics
Business Units. Prior to his tenure at Bayer, Mr. Pucci held positions
of increasing responsibility with Eli Lilly, culminating with his
appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci holds
an MBA from the University of Chicago and is a graduate of the
Universita Degli Studi Di Napoli in Naples, Italy.
Dyax is a fully integrated biopharmaceutical company focused on
discovering, developing and commercializing novel biotherapeutics for
unmet medical needs. The Company's lead product, ecallantide, has been
approved under the brand name KALBITOR® in the United States
for the treatment of acute attacks of hereditary angioedema (HAE) in
patients 16 years of age and older.
Dyax is commercializing KALBITOR in the United States independently, and
establishing strategic partnerships to develop and commercialize
ecallantide for the treatment of HAE in key regions worldwide.
Currently, Dyax has partnership agreements for regions including Europe,
Japan, Russia, the Middle East, Israel, North Africa, Australia, New
Zealand, Latin America (excluding Mexico), the Caribbean, Taiwan,
Singapore and South Korea. The Company is also exploring other potential
indications for ecallantide, either alone or through partnerships,
including drug-induced angioedema.
Ecallantide and other compounds in Dyax's pipeline were identified using
its patented phage display technology, which rapidly selects compounds
that bind with high affinity and specificity to therapeutic targets.
Dyax leverages this technology broadly through the Licensing and Funded
Research Program (LFRP), which has approximately 75 revenue generating
licenses and collaborations for therapeutic discovery, as well as for
affinity separations, diagnostic imaging, and research reagents. The
success of the Company's LFRP royalty portfolio is illustrated by the
program's advanced licensee pipeline that includes 17 candidates in
clinical development. Of those candidates, four are in Phase 3 clinical
trials, four are in Phase 2 and nine are in Phase 1.
This press release contains forward-looking statements. Statements that
are not historical facts are based on Dyax's current expectations,
beliefs, assumptions, estimates, forecasts and projections about the
industry and markets in which Dyax and its licensees compete. The
statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and assumptions,
which are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed in such forward-looking
statements because of uncertainties involved in any future projections,
as well as uncertainties associated with various activities and aspects
of Dyax's business. These risks and uncertainties are described or
referred to in Item 1A, "Risk Factors" in Dyax's most recent Annual
Report on Form 10-K and other periodic reports filed with the Securities
and Exchange Commission. Dyax cautions investors not to place undue
reliance on the forward-looking statements contained in this release.
These statements speak only as of the date of this release, and Dyax
undertakes no obligations to update or revise these statements, except
as may be required by law.
Dyax, the Dyax logo, KALBITOR and KALBITOR Access are registered
trademarks of Dyax Corp.
George Migausky, 617-250-5733
President and Chief Financial Officer
Source: Dyax Corp.
News Provided by Acquire Media
Close window | Back to top